Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results
- None.
- None.
Insights
The reported increase in revenue and gross profit for Invitae's fourth quarter and full year 2023 is a positive indicator, particularly when considering the reported year-over-year growth. The gross margin expansion from 24.2% to 58.0% in the fourth quarter and from 19.2% to 36.0% for the full year suggests significant improvements in cost management and operational efficiency. However, the decline in annual revenue and the substantial cash burn of $365.0 million for the year, despite the debt repayment, raise concerns about the company's liquidity and long-term financial sustainability.
Investors should note the pro forma adjustments that account for discontinued operations when evaluating the company's performance. These adjustments provide a clearer picture of the ongoing business but also require careful analysis to understand the underlying business trends. The net decrease in cash reserves from $557.1 million to $209.0 million year-over-year is significant and it indicates that despite positive growth metrics, the company is consuming cash at a rapid rate, which could lead to the need for additional capital infusions or cost-cutting measures in the future.
The medical genetics industry is characterized by high research and development costs, which is reflected in Invitae's financials. The revenue growth on a pro forma basis suggests that the company is growing its core business, which is a positive sign for its market position. However, the competitive landscape of the medical genetics sector must be taken into account, as it may affect the company's ability to sustain and increase its market share.
Additionally, the cash burn reported by Invitae is not uncommon in the biotech and medical genetics industries, where companies often operate at a loss while investing heavily in technology and market expansion. Stakeholders should consider the potential for future revenue growth against the risks associated with the high burn rate and the possibility of dilutive financing or strategic partnerships that may be necessary to fund operations.
The growth in gross profit and gross margin suggests that Invitae is potentially realizing the benefits of economies of scale or has made strides in enhancing its operational efficiencies within the medical genetics field. This could be the result of advancements in gene sequencing technologies or improved data analysis capabilities, which can lead to cost reductions and improved margins.
However, the financial health of a company in this sector is also heavily dependent on its pipeline and the ability to bring new tests and services to market. The ongoing cash burn may be a reflection of necessary investments in research and development, which could yield significant returns if successful. It is crucial to analyze the company's R&D strategy and its alignment with industry trends, such as personalized medicine and companion diagnostics, which are rapidly gaining traction.
Estimated unaudited financial results for fourth quarter 2023
- Fourth quarter 2023 revenue was
, an increase of approximately$127.8 million 4% from a year ago. After adjusting for revenue of approximately in the prior year period related to the discontinued businesses, fourth quarter 2023 revenue increased approximately$10.5 million 14% on a pro forma basis. - GAAP gross profit was
in the fourth quarter of 2023, compared to$74.1 million a year ago, representing an approximate$29.6 million 150% year-over-year growth. Non-GAAP gross profit was in the fourth quarter of 2023, compared to$74.4 million a year ago, representing year-over-year growth of approximately$58.5 million 27% . - Fourth quarter GAAP gross margin was
58.0% compared to24.2% a year ago. Non-GAAP gross margin was58.2% in the fourth quarter of 2023, compared with47.8% in the fourth quarter of 2022. - In the fourth quarter of 2023, net decrease in cash, cash equivalents, restricted cash and net changes in investments was
. Reported cash burn in the fourth quarter of 2023 was$56.5 million and included$53.6 million from asset sales related to YouScript. Excluding the asset sales related to YouScript, ongoing cash burn would have been$4.0 million .$57.6 million
Estimated unaudited financial results for fiscal year 2023
- Fiscal year 2023 revenue was
, approximately$487.0 million 6% lower than in fiscal year 2022. The decline was due to the exited businesses and geographies. After adjusting for revenue of approximately$516.3 million in the prior year period related to those discontinued businesses, fiscal year 2023 revenue increased approximately$62.1 million 7% on a pro forma basis. - GAAP gross profit was
in 2023, compared with$175.2 million in 2022, representing approximately$99.1 million 77% year-over-year growth. Non-GAAP gross profit was in 2023, compared with$254.2 million in 2022, representing year-over-year growth of approximately$219.7 million 16% . - GAAP gross margin was
36.0% in 2023, compared to19.2% in 2022. Non-GAAP gross margin was52.2% in 2023, compared to42.5% in 2022. - As of December 31, 2023, Invitae had
of cash, cash equivalents, restricted cash and marketable securities compared to$209.0 million as of December 31, 2022. In fiscal year 2023, net decrease in cash, cash equivalents, restricted cash and net changes in investments was$557.1 million . Reported cash burn in 2023 was$355.3 million and included$365.0 million of debt repayment and prepayment fees, as well as$143.1 million from asset sales related to YouScript. Excluding the debt related payments and asset sales related to YouScript, ongoing cash burn would have been$4.0 million .$225.9 million
Invitae has not completed preparation of its financial statements for the fourth quarter or full year 2023. The estimated unaudited financial results presented in this press release for the fourth quarter and full year ended December 31, 2023 are based on Invitae's current expectations and are subject to adjustment. Our independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to this estimated unaudited financial data, or the accounting treatment thereof, and does not express an opinion or any other form of assurance with respect thereto. While we are currently unaware of any items that would require us to make adjustments to the financial information set forth herein, it is possible that we or our independent registered public accounting firm may identify such items as we complete our fourth quarter and full year 2023 financial statements, and any resulting changes could be material. Accordingly, undue reliance should not be placed on these estimates.
About Invitae
Invitae (OTC: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.
To learn more, visit invitae.com and follow for updates on LinkedIn, X, Instagram, and Facebook @Invitae.
Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including the company's 2023 estimated unaudited financial results, including revenue, gross profit, gross margin and cash burn. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: actual results for the fourth quarter and full year 2023; the year-end close process and audit of the company's financial statements; risks and uncertainties regarding the company's ability to successfully consummate and complete a plan of reorganization under Chapter 11; the company's ability to continue operating in the ordinary course while the Chapter 11 cases are pending; potential adverse effects of the Chapter 11 cases on the company's business, financial condition, liquidity and results of operations; and the other risks and uncertainties disclosed in the Company's annual and quarterly periodic reports and other documents filed with the SEC. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.
Non-GAAP Financial Measures
To supplement the company's estimated unaudited financial results for the fourth quarter and year ended December 31, 2023 prepared in accordance with generally accepted accounting principles in
Other companies, including companies in the same industry, may not use the same non-GAAP measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-GAAP measures as comparative measures. Because of these limitations, the company's non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the non-GAAP reconciliations provided in the tables below.
Contacts for Invitae:
Investor Relations
Hoki Luk
ir@invitae.com
Public Relations
Amy Sands Hadsock
pr@invitae.com
INVITAE CORPORATION | ||||||||
Reconciliation of GAAP to Non-GAAP Gross Profit | ||||||||
(in thousands) | ||||||||
(unaudited) | ||||||||
Three Months Ended December 31, | Year Ended December 31, | |||||||
2023 | 2022 | 2023 | 2022 | |||||
Revenue | $ 127,847 | $ 122,454 | $ 486,976 | $ 516,303 | ||||
Cost of revenue | 53,713 | 92,844 | 311,815 | 417,256 | ||||
Gross profit | 74,134 | 29,610 | 175,161 | 99,047 | ||||
Amortization of acquired intangible assets | — | 26,950 | 77,122 | 100,568 | ||||
Acquisition-related stock-based compensation | 26 | 156 | 172 | 581 | ||||
Acquisition-related post-combination expense | — | — | — | 1,053 | ||||
Restructuring-related retention bonuses | 105 | 82 | 250 | 252 | ||||
Inventory and prepaid write-offs | 92 | 1,712 | 1,454 | 18,179 | ||||
Non-GAAP gross profit | $ 74,357 | $ 58,510 | $ 254,159 | $ 219,680 |
Reconciliation of Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash to Cash Burn | |||||||||
(in thousands) | |||||||||
(unaudited) | |||||||||
Three Months Ended | Year Ended | ||||||||
March 31, 2023 | June 30, 2023 | September 30, | December 31, | December 31, | |||||
Net cash used in operating activities | $ (34,398) | $ (54,905) | $ (66,895) | $ (50,076) | $ (206,274) | ||||
Net cash provided by investing activities | 73,878 | 116,064 | 5,117 | 72,675 | 267,734 | ||||
Net cash (used in) provided by financing activities | (135,768) | 876 | (3,381) | (7,197) | (145,470) | ||||
Net (decrease) increase in cash, cash equivalents and restricted cash | (96,288) | 62,035 | (65,159) | 15,402 | (84,010) | ||||
Adjustments: | |||||||||
Net changes in investments | (75,202) | (117,146) | (7,048) | (71,917) | (271,313) | ||||
Loss from public offerings of common stock, net of issuance costs | — | — | 55 | — | 55 | ||||
Proceeds from issuance of Series B convertible senior secured notes due 2028, net of issuance costs | (22,435) | 1,763 | 8,016 | 2,929 | (9,727) | ||||
Cash burn(1) | $ (193,925) | $ (53,348) | $ (64,136) | $ (53,586) | $ (364,995) | ||||
(1) Cash burn for the three months ended March 31, 2023 includes | |||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/invitae-reports-estimated-unaudited-fourth-quarter-and-full-year-2023-financial-results-302080793.html
SOURCE Invitae Corporation
FAQ
What was Invitae's revenue in Q4 2023?
What was the GAAP gross profit in Q4 2023?
How did the FY 2023 revenue compare to FY 2022 for Invitae?
What was the non-GAAP gross profit in FY 2023?
What was the cash burn in Q4 2023?